Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aldoxorubicin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CytRx Partners with Oncology Development Expert to Advance LADR Platform
Details : Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in ...
Brand Name : INNO-206
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 20, 2022
Lead Product(s) : Aldoxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Centurion BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Details : Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for sharehol...
Brand Name : INNO-206
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2022
Lead Product(s) : Aldoxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Centurion BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2022
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ImmunityBio continues to study the effectiveness of N-803 and aldoxorubicin in combination with PD-L1 thaNK in Phase 1 / 2 clinical trials to treat triple negative breast cancer and head and neck cancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2021
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 2, study will evaluate the comparative efficacy and safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic p...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : ImmunityBio
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : At 12-months, a significant treatment effect in favor of arimoclomol of −1.40 points was observed, corresponding to a 65% relative reduction in annual disease progression.
Brand Name : Miplyffa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2021
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CytRx Highlights Preliminary Results of Cohort C of QUILT 88
Details : Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first qu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2021
Lead Product(s) : Aldoxorubicin HCl,Paclitaxel,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Orphazyme stated arimoclomol demonstrated a consistent safety profile throughout the 36-month treatment period. Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs).
Brand Name : Miplyffa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2021
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol
Details : CytRx has received a Complete Response Letter from the U.S. Food and Drug Administration following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C.
Brand Name : Miplyffa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 18, 2021
Lead Product(s) : Arimoclomol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : NantKwest
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 15, 2021
Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : NantKwest
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?